# REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

> **NCT05632809** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 39 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** NKTR-255
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05632809
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05632809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05632809, "REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05632809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*